Arildone is an aryl diketone which is inhibitory in vitro against herpes simplex virus type 2 at a concentration of 2 ,ig/mi or less. One hundred forty-five patients with recurrent genital herpes were enrolled in a multicenter, randomized, placebo-controlled, double-blind trial to evaluate the efficacy and safety of an 8% arildone cream. Patients initiated therapy a mean of 9.9 h and a maximum of 24 h after the reported onset of lesions and applied medication 6 times daily for 7 days. The duration of viral shedding was shorter among women (P < 0.05) and the duration of local itching was shorter among men (P < 0.05) in patients that received arildone than in those that received placebo, but there were no significant differences between treatment groups in duration of pain, time to crusting or healing of lesions, or percentage of patients developing new lesions. Mild local irritation after application of ointment was common and occurred equally in both treatment groups. Despite early application, topical arildone cream was ineffective in the therapy of acute recurrences of genital herpes.
Recurrent genital herpes is a common sexually transmitted disease; 80 to 90% (4) of the estimated 300,000 patients (1, 3) who experience first episodes of disease in the United States per year will have subsequent recurrences at a mean rate of four to five per year (4) . Oral acyclovir, a recently licensed antiviral agent which acts by inhibiting viral DNA polymerase (6) , shortens the duration of recurrent episodes of genital herpes (15) and, when used on a daily basis, can suppress recurrences altogether (5, 13, 17) . There are concerns, however, over the potential for toxicity of a frequently used, systemically active DNA inhibitor and over the possibility of emergence of acyclovir-resistant herpes simplex virus (HSV) (7, 17, 19) . Arildone (WIN 38020), an aryl diketone compound with broad-spectrum in vitro activity against a variety of RNA and DNA viruses (8, 18) , including HSV (10), appears to have a unique mechanism of antiviral action. It inhibits replication of poliovirus at an early step by preventing virion uncoating (12) , and it has been found to protect against poliovirus-induced disease in mice (11) . Its activity against HSV, although less well defined, also occurs early postinfection and prevents synthesis of both viral DNA and proteins (10) . Furthermore, arildone is reported to be equally effective in vitro against both acyclovir-sensitive and acyclovir-resistant isolates (A. S. Tyms 6 times a day for 7 days. After the enrollment visit (day 0), patients were seen in the clinic on the first 3 days; on days 4 or 5; days 6 or 7; days 8, 9, or 10; or days 11, 12, or 13; thereafter, they were seen every 2 to 3 days until their lesions healed. At each visit, patients were questioned regarding local symptoms, possible adverse effects, and medication compliance; and their lesions were examined and cultured. The number, size, and location of lesions were recorded at each visit; and lesions were classified as macular, papular, vesicular, pustular, ulcerative, crusted, or healed. The areas of individual lesions were estimated by multiplying the greatest length by the greatest width, and these were summed to yield a total lesion area. Lesions developing after day 0 were categorized as new lesions and were evaluated separately.
Virologic studies. All lesions present at day 0 were cultured at each visit with one swab, moving from the oldest lesion to the most recent; new lesions were cultured separately. To minimize problems with drug carry-over from lesions to culture media, patients were asked not to begin daily applications of medication until after their visit to the clinic. In addition, lesions were lightly rinsed with saline-saturated cotton gauze and then air-dried before they were cultured. Lesions in various stages were cultured with dacron-tipped swabs (Inolex, Chicago, Ill.) as follows: macular and papular, swab of lesion surface; vesicular and pustular, swab of fluid and lesion base after rupture of vesicle or pustule with a needle; and ulcer and crust, swab of lesion base. Culture swabs were placed in 1.5-ml vials of cold viral transport media, agitated, and removed. Transport media was held at 4°C until inoculation within 72 h of susceptible monolayer cell cultures. After a 1-h period of absorption, the cells were washed 3 times with maintenance media and then incubated at 37°C. Cell lines employed included mink lung cells (Salt Lake City), human embryonic lung (Denver), human embryonic tonsil (Seattle), and WI-38 (Syracuse). Cultures were read daily for at least 7 days and were considered positive for HSV on the basis of characteristic cytopathic effects. Quantitation of viral infectivity was determined on frozen (-70°C) aliquots from specimens from 66 of 91 culture-positive patients from day 0.
Monitoring for drug toxicity. On days 0 and 6 or 7 a urinalysis was performed; and blood was obtained for determination of a complete blood count and leukocyte differential, platelet and reticulocyte counts, and routine serum chemistries (including serum creatinine, bilirubin, and alanine aminotransferase).
Statistical analysis. Baseline demographic characteristics were compared by analysis of variance and x2 tests. Comparisons of duration of symptoms and characteristics of lesions pretreatment (day 0) were performed by Student's t test and the x2 test. Evaluation of the effects of treatment on the duration of symptoms and viral shedding at the time of crusting and healing of lesions was carried out by use of the Mantel-Cox log rank test (14) ; these results were calculated for all evaluable patients as well as for only those whose cultures were positive for HSV. For descriptive purposes these results are expressed as mean values. The duration of viral shedding was defined as the time from entry into the study until the first culture-negative visit after the last culture-positive visit. Durations of pain and itching were calculated from day 0 until the day the patient first reported the loss of the symptom. Only patients reporting a symptom were included in the analysis of that symptom. Time to crusting or healing was calculated as number of days from entry into the study until the first clinic visit when an investigator noted, respectively, that all remaining lesions were crusted or re-epithelialized. The frequency of new lesion formation and occurrence of adverse reactions were evaluated by the x2 test. Consistency of data among the four centers was evaluated by analysis of variance. No baseline characteristic varied significantly (P < 0.05) by both center and therapy group except for duration of lesions prior to initiation of therapy, and even then the range (5.9 to 14.2 h) was small. There were no differences among the centers for parameters of clinical outcome, i.e., duration of viral shedding, pain, or itching or time to crusting and healing of lesions. RESULTS Characteristics of the study population. A total of 170 patients with a clinical diagnosis of recurrent genital herpes were enrolled in this study. Twenty-five patients did not complete the treatment regimen and were excluded from analysis. Of the remaining 145 patients, 69 were men and 76 were women; 71 received arildone and 74 received placebo. Of 145 patients, 110 (76%) (51 of whom received arildone and 59 of whom received placebo) had HSV isolated from external genital lesions. Cultures from 91 (83%) patients were positive at the first visit, and cultures from 19 patients were positive at a subsequent visit only.
Age; ethnicity; mean frequency and duration of prior episodes of genital herpes; and number, duration, viral titer, area, and stage of lesions at the initiation of therapy were similar between treatment groups (Table 1) . At the time of first treatment, mean number, duration, viral titer, and area of lesions were 2.7, 9.9 h, 102-6, and 58 mm2, respectively; 30% of patients had vesicular or pustular and 49% had ulcerative lesions. There were no differences between men and women in mean duration of lesions (8. Effect of treatment on the duration of viral shedding, lesions, and symptoms. The mean duration of viral shedding was evaluated in the 91 patients who were culture positive at the initiation of therapy. Among the 43 women, viral shedding was significantly shorter in recipients of arildone than in recipients of placebo (3.2 versus 4.0 days; P < 0.05), although there was no significant difference among the 48 men (Table 2 ). Other efficacy parameters were analyzed for all 145 evaluable patients. Among the 69 evaluable men, the mean duration of symptoms was shorter in arildone than placebo recipients for pain (2.3 versus 3.6 days; P = 0.06) and itching (2.3 versus 3.2 days; P < 0.05), although among the 76 evaluable women, these differences were smaller and not significant. Similarly, for men, the mean time to crusting was shorter in arildone-treated patients than in placebotreated patients (3.3 versus 4.3 days; P = 0.05). Healing times were also slightly shorter in arildone-treated than placebo-treated men (6.8 versus 7.8; P > 0.10), but this difference was not significant. In women, mean times to crusting and healing were similar for both treatment groups. Finally, the proportion of patients in which new lesions formed were similar in arildone and placebo recipients for men (36 versus 24%; P > 0.10) and women (28 versus 22%; P > 0.10) both.
Among the subset of 48 men and 43 women who were viral culture positive at day 0, trends in duration of symptoms and lesions were similar to those seen for the entire group. For men, the mean duration of pain and itching and time to ANTIMICROB. AGENTS CHEMOTHER. crusting and healing of lesions were slightly shorter among each. No other adverse symptoms were described, and no the 22 arildone recipients (mean values of 2.7, 2.0, 3.1, and significant laboratory abnormalities were noted in either 6.6 days, respectively) than among the 26 placebo recipients group.
(mean values of 3.9, 3.1, 4.7, and 7.9 days, respectively; P > 0.05 for all comparisons). For women, there were no differ-DISCUSSION ences in mean duration of pain and itching and time to crusting and healing between the 21 arildone recipients
Our results indicate that an 8% cream formulation of (mean values of 3.0, 3.4, 3.8 and 8.0 days, respectively) and arildone has a minimal effect on the clinical course of the 22 placebo recipients (mean values of 3.2, 3.0, 4.4, and recurrent genital herpes, despite initiation of therapy a mean 7.4 days, respectively; P > 0.10 for all comparisons). The of 9.9 h after the reported onset of lesions. Although results were similar when all 110 patients culture positive at duration of itching and pain and time to crusting of lesions any time during the study were analyzed.
were shorter among all evaluable men, these differences Adverse reactions. Medication was discontinued due to were not significant in the subgroup of men with cultureadverse effects in 1 of 145 evaluable patients. This patient, a positive lesions. Furthermore, no significant differences women receiving arildone, noted burning and pain lasting up were found in the more objective endpoints of duration of to 15 min after medication application. Overall, irritation viral shedding, proportion of patients forming new lesions, with application of medication, lasting a mean of 19.7 min or time to total healing. For women, despite a shorter (range 2 to 180 min) was reported by 29 of 72 (41%) arildone duration of viral shedding among arildone recipients, there and 33 of 74 (45%) placebo recipients (P > 0.10). The rates were no significant differences in duration of pain or itching, of local irritation varied by sex, occurring in 24 of 69 (35%) time to crusting or healing, or proportion of patients in which of men and 38 of 76 (50%) of women (0.10 > P > 0.05), and new lesions formed. Both arildone cream and the placebo by center: Salt Lake City (2 of 53 patients; 4%), Denver (23 formulation were commonly associated with transient local of 45 patients; 51%), Seattle (20 of 27 patients; 74%), and irritation at the site of application. The large variation by Syracuse (17 of 20 patients; 85%) (P < 0.001). Skin rash and center in the frequency of this symptom attests to the labial edema were noted by one female placebo recipient difficulty in standardizing the elicitation of adverse effects 
